News Release

Yamanouchi Pharmaceutical Co., Ltd.

Manufacturing and Import of Micardis, New Oral Therapy for Hypertension, is Approved

October 9 ,2002

Nippon Boehringer Ingelheim Co., Ltd. obtained on 8 October the manufacturing and import approval of Micardis, new oral therapy for hypertension. Micardis will be co-promoted by Nippon Boehringer Ingelheim and Yamanouchi Pharmaceutical Co., Ltd. and distributed through Yamanouchi's channel. The brief outline of the approval is as follows.

Date of Approval : 8 October 2002
Brand Name : Micardis Capsule 20mg/Micardis Capsule 40mg
Generic Name : telmisartan
Class : angiotensin II receptor blocker
Indication : hypertension
Manufacturer : Nippon Boehringer Ingelheim Co., Ltd.

Micardis is an angiotensin II receptor blocker for the treatment of hypertension alone or in combination with other antihypertensive agents.
Micardis demonstrates excellent clinical benefits (both efficacy and safety) through controlling blood pressure when given once daily over a 24 hour period - especially during early morning hours, the period of a day with the highest risk for myocardial events.

Micardis has been discovered and internationally developed by Boehringer Ingelheim group of companies. Nippon Boehringer Ingelheim has clinically developed the drug in Japan and submitted new drug application in January 2001. The drug will be manufactured by Nippon Boehringer Ingelheim and distributed through Yamanouchi's channel. Sales of Micardis will be started immediately after the drug price is listed. In close cooperation, the two companies will enhance their activities in providing promotional and scientific information to the medical community and will effectively promote the innovative feature of this product to medical professionals.

Micardis is on the market in over 65 countries, including the U.S. and major European countries around the world.

<Company Profiles>
Nippon Boehringer Ingelheim Co., Ltd.(
Establishment : June 1961
Head Office : 3-10-1, Kawanishi-shi, Hyogo, Japan
President : Akio Ohsawa
Annual Net Sales : 79.3 billion yen (as of December 2001)
Number of Employees : 1,602 (as of December 2001)
Major Business : - Research & development, import, manufacturing, and marketing of pharmaceuticals
- Import/export and marketing of pharmaceutical active ingredients and intermediates

Boehringer Ingelheim GmbH (
Establishment : 1885
Head Office : Ingelheim, Germany
Representative : Prof. Rolf Krebs (Chairman of the Board)
Consolidated Net Sales : EUR 6,694 million (as of December 2001) / about 728 billion yen
Consolidated Number
of Employees
: About 28,000
Major Business : Research & Development, manufacturing, and marketing of prescription medicine, consumer healthcare products, animal health product, bio-pharmaceuticals, and chemicals
Operation Sites : 143 affiliated companies around the world

Yamanouchi Pharmaceutical Co., Ltd.
Establishment : April 1923
Head Office : 3-11, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo, Japan
President : Toichi Takenaka
Consolidated Net Sales : About 480 billion yen (as of March 2002)
Consolidated Number
of Employees
: About 9,300
Major Business : Developing, manufacturing, and import, export, and marketing pharmaceuticals, consumer health care, foods, medical equipment